Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous Pembrolizumab in rrcHL and rrPMBCL
NCT06504394Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Oct 2024
- Primary completion
- Nov 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 11
01
Overview
A Phase 2 trial of pembrolizumab in classical Hodgkin lymphoma (cHL), primary mediastinal large B-cell lymphoma (PMBCL), sponsored by Merck & Co.. Started Oct 2024; status: active, not recruiting.
02
Drugs
03
Conditions
classical Hodgkin lymphoma (cHL)primary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on NCT06504394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06504394.